ArticleNeuropsychiatric disease and treatment2025
Increased Antidepressant Prescriptions for Children and Adolescents with Major Depressive Disorder in Japan Based on a Claims Database.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Population-Based Trends in Antidepressant Dispensing Among Children and Adolescents in Manitoba, Canada.Pharmacoepidemiology and drug safety · 2026Article
- Real-World Antidepressant Treatment Persistence in Children and Adolescents with Major Depressive Disorder in Japan: A Retrospective Nationwide Claims-Based Study.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Currently, no therapeutic antidepressants are approved for pediatric patients with major depressive disorder (MDD) in Japan. In addition, few longitudinal studies have been conducted in Japan on antidepressant prescriptions for children and adolescents with MDD. The purpose of this study is to clarify the actual pharmacotherapy for child and adolescent patients with MDD during fiscal year (FY) 2010-FY2017. Patients and Methods: We investigated trends in the prescription of antidepressants and concomitant psychotropic drugs for child and adolescent patients aged ≤18 years with MDD from FY2010 to FY2017 using a large-scale Japanese health insurance claims database. Results: From FY2010 to FY2017, the database recorded claims for an average of 443,977 patients annually. Antidepressant prescriptions increased year by year, with particularly large increases in the 13-18 age group (4.72/1000 persons in FY2010; 6.14/1000 persons in FY2017). By drug class, a higher proportion of selective serotonin reuptake inhibitors, especially sertraline and escitalopram, were prescribed in any given FY, with an increasing trend in the 13-18 age group (2.64/1000 persons in 2010, 3.55/1000 persons in 2017). However, the overall antidepressant prescription rate among patients with MDD declined gradually, particularly among those in the 13-18 age group (68.7% in FY2010, 57.0% in FY2017). Conclusion: The rate of child and adolescent patients prescribed antidepressants increased, while the antidepressant prescription rate among child and adolescent patients with MDD declined, indicating that Japanese physicians have become more cautious about the use of antidepressants. It is critical to generate new clinical data on the efficacy and safety of antidepressants for Japanese child and adolescent patients with MDD and to consider the development of additional pediatric indications for antidepressant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.